Abstract
Introduction

It is generally accepted that the antigen-driven cellular immune response directed against a particular pathogen, begins in the lymph node by the interaction of naïve T cells with dendritic cells. In the past dendritic cells were regarded as immunostimulatory cells only. However, several different subsets of dendritic cells have been described recently, some of which are capable of inhibiting T-cell responses
.
According to data by the group of Mellor and Munn [3] , the induction of the tryptophan degrading enzyme indoleamine 2,3-dioxygenase has been recognized as an immunoregulatory mechanism. Indoleamine 2, ϩ dendritic cells were characterized as either immunodownregulatory or tolerogenic dendritic cells [4] .
Different pathways leading to IDO induction in dendritic cells have been described and several cytokines (types I and II interferons [IFNs], tumour necrosis factor [TNF]-␣, granulocyte macrophage-colony stimulating factor [GM-CSF], prostaglandin E [PGE]
2) [5] [6] [7] [8] and surface molecules (CTLA4, CD80/86, CD40, CD200) [9] [10] [11] [12] 
have been implicated in IDO induction. In general, most of them are dependent on the presence or production of IFN-␥ [13], while only a few pathways appear to be independent of IFN-␥ [14] Type-1 IFNs seem to be important in specialized CD19
ϩ DC subsets and IDO is additionally involved in the induction of type-1 IFNs in these cells [15] .
Most data have been obtained from macrophages/dendritic cells and therefore the focus has been on the primary or secondary activation of T cells especially within the lymph node. Dendritic cells are the most prominent antigen-presenting cells (APC) in the primary activation of resting, naïve T cells. In secondary T-cell activation and especially also the triggering of the effector phase of T-cell activation in the inflamed tissue, several other cell types can interact with T cells as APC. In human beings, IDO expression can be induced in several non-professional APC (NP-APC) and it can be assumed that IDO activity within these cells is involved in the control of the local T-cell effector phase. Much attention was paid to the role of IDO expression in tumour cells
The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects and it was found that a surprisingly high proportion of cells within human tumours express IDO activity [16] . In line with the fact that IDO expressing tumour cells are capable of inhibiting T-cell proliferation, in vivo studies in mice showed that IDO ϩ tumour cells become resistant to immune eradication [16] . Histological [20, 21] or via dendritic cells [22] . [24, 25] . Starting with the initial finding of Pfefferkorn et al. [26] , a set of different human pathogens have been found to be inhibited by IDO. The exact mechanism of this IDO-mediated antimicrobial effect remains unclear, but it is widely accepted that depletion of tryptophan is responsible for the antiparasitic effect [27] . Until [28] , epithelial cells [29] , fibroblasts [26] and astrocytes [30] 
Materials and methods
Media and cells
Kynurenine assay
Supernatants harvested from IFN-␥-stimulated cells were analysed for their kynurenine content, using Ehrlich reagent as described before [32] . As a standard we diluted kynurenine (Sigma-Aldrich) in culture medium. For the calculation of the kynurenine content in the supernatant, linear regression and GraphPad Prism software was used.
Determination of bacterial growth
For the analysis of bacterial growth in conditioned medium, several strains of staphylococci or enterococci, obtained from routine diagnostic specimens were used. The IDO sensitivity of these strains has been previously analysed [33, 34] 
High-performance liquid chromatography (HPLC) analysis
Results
Inhibition of the efferent arm of the immune system by IDO ϩ bystander cells 
It is well described that IDO ϩ NP-APC, such as mesenchymal stroma cells, fibroblasts and epithelial cells, as well as cells from different tumour lines, are capable of mediating inhibitory effects on T cells in an IDO-dependent fashion, when they are present as bystander cells during T-cell activation [35-37]. We assume that this immunoregulatory effect, mediated by NP-APC, does not have an incidental bystander function but rather is ubiquitously present as a part of the IFN-␥ stimulation, resulting from inflammation. We have previously shown that immortalized human brain microvascular cells (HBMEC) are able to inhibit T-cell responses in an IDO-dependent fashion [38]. In addition, Figs 1-3 demonstrate that different tumour cells for example astrocytoma cells (86HG39), lung carcinoma cells (A549) or cervix carcinoma cells (HeLa) as well as native tissue cells (HFF) are, subsequent to IDO induction by IFN-␥, capable of inhibiting mitogen (PHA), superantigen (SEB), anti-CD3 and alloantigen-driven T-cell activation, when present as bystander cells during T-cell activation. These inhibitory effects could be blocked by the addition of tryptophan as well as by the addition of the IDO specific inhibitor 1-methyl-tryptophan. Further experiments indicated that the inhibitory effect mediated by NP-APC, present as bystander cells, was dependent on the number of cells present during T-cell acti
3). As a control, supernatants from IFN-␥-activated Jurkat cells or from epstein-barr virus (EBV)-transformed B-cells, which do not express IDO activity, were used and did not influence T-cell proliferation (data not shown).
In (Fig. 5A) .
In a third experimental setting, the same supernatants that were used to determine kynurenine content and to measure bacterial growth, were also used to analyse T-cell activation induced by cross-linking anti-CD-3 antibodies. As shown in Fig. 4C, T- 
cells are capable of inhibiting mitogen-driven T-cell proliferation: Mitomycin-treated 86HG39 cells (A) or irradiated A549 cells (B) were incubated with or without IFN-␥ (500 U/ml). After 3 days, 1.5 ϫ 10
PBL were added and stimulated with anti-CD3 antibodies, phytohemagglutinin A or staphylococcal enterotoxin B for additional 3 days in the absence or presence of tryptophan (100 g/ml). T-cell proliferation was determined by 3 H-thymidine incorporation after 3 days. Data are given as mean Ϯ S.E.M. of two independent experiments, each done in triplicate. Asterisks indicate significant inhibition of T-cell responses (P Ͻ 0.005). concentration mediate inhibitory effects on T-cell growth. This is supported by data obtained by analysing T-cell proliferation in the presence or absence of different amounts of kynurenine with or without supplemental tryptophan, as shown in Fig. 5B. In summary, these experiments combine the tryptophan starvation and the toxic metabolites hypotheses and therefore confirm that both hypotheses are not mutually exclusive. Furthermore, this is the first report, to our knowledge, which documents an analysis of the mechanism of IDO-mediated antibacterial and immunoregulatory effects in parallel since most groups focus either on the immunoregulatory or the antimicrobial function of this enzyme.
A difference in the tryptophan requirement combines IDO-mediated antimicrobial and immunoregulatory effects
We have recognized that IDO ϩ NP-APCs are capable of inhibiting both T-cell proliferation and bacterial growth. These two IDO-mediated effects seem to be contradictory in terms of a unifying immune defence hypothesis. To analyse the relationship between IDO-mediated antimicrobial and immunoregulatory effects in more detail, we aimed to define the threshold concentration of tryptophan, necessary to mediate both effects. Therefore, we once again used supernatants harvested from IDO ϩ cells to determine bacterial growth and T-cell growth and supplemented these conditioned media with different amounts of tryptophan. Figure 6B shows the bacterial growth, measured by determining optical density. These data indicate that bacterial growth is blocked in the supernatant of IFN-␥-stimulated cells and that this antibacterial effect could be restored by the addition of tryptophan. A 50% inhibition of bacterial growth was found at a tryptophan concentration of about 0.38 g/ml (1.9 M). The same supernatants were also used to culture T cells and the data in Fig. 6A indicate that T-cell proliferation in medium, conditioned by IFN-␥ activated A549 cells, is reduced by about 70%. A half-maximal inhibition of T-cell growth was achieved at a
tryptophan concentration of about 0.02 g/ml (0.1 M) (Fig. 6) (Fig. 7) . groups showing IDO-dependent growth inhibition of parasites [26, 39] , bacteria [40, 41] and viruses [29, 42] . However, to date only indirect in vivo evidence for the involvement of IDO in the antimicrobial defence has been described. For example, increased concentrations of kynurenines were found in the cerebrospinal fluid of patients with HIV-encephalitis [43] . In mice infected with Plasmodium berghei, IDO protein was detected immunohistochemically within endothelial cells [44] . Furthermore, in toxoplasma-infected mice a dramatic drop in the tryptophan concentration in lung tissue was accompanied by an increase in kynurenine concentration [45] . [53, 54] , is still 4 times lower than the threshold concentration for bacteria, measured by us using the CFU-method (Fig. 6C) .
Altogether, these data indicate that the tryptophan need of bacteria is higher than the tryptophan need of T cells. This led us to the conclusion that a comparably lesser tryptophan degradation mediates an antibacterial effect whereas a 10-40-fold stronger tryptophan depletion is necessary to mediate an immunoregulatory effect.
Discussion
The widely accepted understanding that IDO is an antimicrobial effector mechanism is derived from in vitro data published by different © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
In contrast, IDO-mediated effects in mice in vivo have been described in the fields of transplant immunology, tumour immunology and in autoimmune and allergic diseases. For example, the inhibition of IDO by 1-MT in vivo resulted in a worsening of the symptoms in an experimental autoimmune encephalomyelitis model [46] and the induction of IDO in dendritic cells has been shown to block the development of diabetes in nonobese-diabetic (NOD) mice [47]. In both examples, IDO induction in professional APC is necessary. In transplant immunology and
Fig. 5 Different effects of kynurenine on the proliferation of T cells and bacteria. Staphylococcal growth in presence of different concentrations of kynurenine was analysed photometrically (A). Anti-CD3-driven T-cell activation was analysed in absence or presence of different concentrations of kynurenine (B). In both experiments, a part of the cultures was supplemented with tryptophan (100 g/ml). Data are given as mean Ϯ S.E.M. of three independent experiments, each done in triplicate.
Fig. 6 Differences in the tryptophan requirement between T cells and bacteria. Supernatants harvested from A459 cells, incubated with or without IFN-g (1000 U/ml), were used as culture medium. Anti-CD3-driven T-cell proliferation in conditioned medium in the presence or absence of different concentrations of supplemental tryptophan (A). Staphylococcal growth in conditioned medium in the presence or absence of different concentrations of supplemental tryptophan was determined photometrically (B) or using the cultivation method (C
In 
